Langerman Alexander, Maccracken Ellen, Kasza Kristen, Haraf Daniel J, Vokes Everett E, Stenson Kerstin M
Department of Surgery, Section of Otolaryngology, Head and Neck Surgery, University of Chicago, Chicago, IL 60637, USA.
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95. doi: 10.1001/archotol.133.12.1289.
To review the incidence of aspiration after chemoradiation therapy in patients with head and neck cancer (HNC).
Retrospective review.
Academic institution.
One hundred thirty patients with advanced HNC underwent chemoradiation therapy at our institution between 1998 and 2002 as part of a larger, multi-institutional, prospective study of induction chemotherapy followed by chemoradiation therapy; the 118 patients (91%) for whom oropharyngeal motility (OPM) study data were available are discussed in this article.
Incidence of trace (</= 5% of swallowed bolus) and frank (> 5%) aspiration (deep laryngeal or tracheal penetration) as determined by pretreatment and posttreatment OPM studies and correlation of the findings with the patients' reported symptoms.
Eighty-one patients (69%) underwent at least 1 OPM study demonstrating aspiration within the first year after chemoradiation therapy, with 30 (25%) demonstrating frank aspiration. Of the patients who aspirated, 61 (75%) reported no symptoms of coughing or choking (80% of trace and 67% of frank aspirators). The patients with cancer of the larynx and hypopharynx were more likely to be aspirators (P = .007 and P = .004, respectively). Of the 62 patients with available pretreatment OPM data, 33 (53%) demonstrated aspiration at baseline.
Aspiration is highly prevalent among patients with advanced HNC at baseline and is worse in the posttreatment period after chemoradiation therapy. The majority of these patients report no symptoms. All patients with advanced HNC should undergo instrumental swallow assessment, even in the absence of symptoms, to detect subclinical aspiration and to institute therapeutic maneuvers and swallow precautions as well as to determine the safety of oral feeding.
回顾头颈部癌(HNC)患者放化疗后误吸的发生率。
回顾性研究。
学术机构。
1998年至2002年间,130例晚期HNC患者在本机构接受了放化疗,这是一项更大规模的多机构前瞻性诱导化疗后放化疗研究的一部分;本文讨论了118例(91%)有口咽运动功能(OPM)研究数据的患者。
通过治疗前和治疗后的OPM研究确定微量(≤吞咽团块的5%)和明显(>5%)误吸(深喉或气管穿透)的发生率,以及研究结果与患者报告症状的相关性。
81例(69%)患者在放化疗后的第一年内至少进行了1次OPM研究,显示有误吸,其中30例(25%)为明显误吸。在有误吸的患者中,61例(75%)报告没有咳嗽或呛噎症状(微量误吸者中80%,明显误吸者中67%)。喉癌和下咽癌患者更易发生误吸(分别为P = 0.007和P = 0.004)。在62例有治疗前OPM数据的患者中,33例(53%)在基线时显示有误吸。
晚期HNC患者基线时误吸非常普遍,放化疗后的治疗期情况更糟。这些患者中的大多数没有症状报告。所有晚期HNC患者即使没有症状也应接受仪器吞咽评估,以检测亚临床误吸,采取治疗措施和吞咽预防措施,并确定经口进食的安全性。